Pharmacological agents that enhance endogenous EPO production (e.g., HIF-PHD inhibitors) may offer dual benefits in anemia and energy metabolism disorders, though risks like erythrocytosis must be carefully managed [55]. The gene discussed is PDC; the disease is anemia.